Saturday, March 15, 2008

A CME-Certified Conference
Testosterone Update
1st Annual Conference on Improving Clinical Outcomes in Hypogonadism

Click here to download the Invitation         Click here to download the Agenda

7:00 AM Registration
8:00 AM Welcome and Program
1:00 PM Adjourn/Box Lunch
 
Fowler Museum at UCLA
308 Charles E. Young Drive North
Harry and Yvonne Lenart Auditorium
Los Angeles, California
 
diamonds
THIS INVITATION IS OPEN TO ALL MEDICAL PROFESSIONALS.
YOUR COLLEAGUES ARE ALSO WELCOME TO ATTEND.
REGISTRATION IS REQUIRED.
diamonds

This activity was developed for urologists, endocrinologists, and primary care physicians who treat men with hypogonadism. Hypogonadism affects several million men in the United States yet is underrecognized and undertreated. Although prevalence increases with age, management of the disorder is particularly challenging. Symptoms are subtle but not specific, the definition of hypogonadism has been debated for years, testosterone level measurements have not been standardized, assays vary, and few large, randomized clinical trials adequately address prostate safety during long-term therapy. Furthermore, low testosterone levels have been associated with diabetes, insulin resistance, metabolic syndrome, and other comorbidities. It is imperative to better understand this disorder to optimize patient outcomes. This conference will review state-of-the-art treatment considerations and provide attendees with the information they need to maximize treatment decisions.

This educational activity is accredited for a maximum of 4.5 AMA PRA Category 1 Credits for physicians.

To register for this CME-certified conference, please complete the following form and click "Submit Form" below. There is no fee to attend this program; however, space is limited. For more information, please call Lori Marrese at CogniMed Inc. at 800-720-7779, ext. 308.

Fields marked with an asterisk (*) are required.

Prefix:
Other (please specify)
*First Name:
Middle Initial:
*Last Name:
*Degree(s):
Other (please specify)
*Specialty:
Other (please specify)
Years in practice:
*Affiliation:
Department:
*Practice type:
Other (please specify)
*Address type:
Address name:
*Address 1:
Address 2:
*City:
*State:
*ZIP:
*Daytime Telephone: (eg, xxx-xxx-xxxx)
Extension:
Cell: (eg, xxx-xxx-xxxx)
Fax: (eg, xxx-xxx-xxxx)
*E-mail:
Best time to contact:
Please indicate any special needs, such as disability access or dietary restrictions:

Please take a minute to answer the following questions before submitting your registration. Thank you.
*1. Which of the following is a sign or symptom of hypogonadism?
a. Increased muscle mass
b. Increased hair growth
c. Fatigue
d. Improved memory
*2. The average age of a patient presenting to the offices of primary care physicians with signs and symptoms of hypogonadism is
a. 50
b. 60
c. 70
d. 80
*3. What percentage of patients who have been diagnosed with hypogonadism are not being treated with testosterone therapy?
a. 50%
b. 70%
c. 85%
d. 95%
*4. Testosterone therapy may improve all of the following symptoms associated with other comorbidities in treating hypogonadism except
a. Osteoporotic changes
b. Urinary flow
c. Depression
d. Sexual dysfunction
*5. Which of the following medical conditions may affect the decision to treat hypogonadism with testosterone therapy?
a. Prostate cancer
b. Congestive heart failure
c. Polycythemia
d. All of the above
*6. The following tools should be used to screen for hypogonadism and monitor testosterone therapy
a. Prostate-specific antigen level, complete blood count, digital rectal examination
b. Electrocardiography, prostate-specific antigen level, complete blood count
c. Chest x-ray, digital rectal examination, urinalysis, liver function test
d. Kidneys ureter bladder x-ray, ultrasonography, electrocardiography
*7. Dosing frequency for a new injectable testosterone formulation, testosterone undecanoate, will likely be
a. Up to every 3 months
b. Monthly
c. Up to every 2 weeks
d. Daily

Privacy Policy

We value the confidentiality of the information you choose to share with us and are committed to its protection. All personal information you provide is stored in a secure location and will never be sold or distributed to any third party.